

## WE CLAIM:

*Sub. B1* → 1. Anti-idiotypic monoclonal antibody 1A7 having all the identifying characteristics of ATCC Accession No. HB-11786.

2. The antibody according to claim 1, wherein said antibody is the internal image of the GD2 ganglioside antigen which is highly expressed on malignant melanoma cell and small cell carcinoma cells.

3. The antibody according to claim 1, wherein said antibody generates an active immunity to GD2 antigen which is highly expressed on malignant melanoma cell and small cell carcinoma cells.

*Sub. B2* → 4. A pharmaceutical composition comprising anti-idiotypic monoclonal antibody 1A7 according to claim 1, and a pharmaceutically acceptable carrier.

5 5. A method of treatment of metastatic melanoma and small cell carcinoma comprising administering a pharmaceutically effective amount of a pharmaceutical composition according to claim 4 to a patient in need of treatment.

6. The method according to claim 5 wherein said patient has had disease removed by surgery, radiation or chemotherapy and remains at high risk for recurrence of metastatic melanoma and small cell lung cancer.

*Sub. B3* → 7. Anti-idiotypic monoclonal antibody 1A7 according to claim 1 wherein said antibody further comprises a detectable label and is a substitute for GD2 antigen in biochemical or serological assays.

B3

8. Anti-idiotypic monoclonal antibody 1A7 according to claim 7, wherein said detectable label is selected from the group consisting of radiolabels, fluorescent labels and chemiluminescent labels.

9. A diagnostic test kit for the detection of melanoma and small cell carcinoma comprising anti-idiotypic monoclonal antibody 1A7.

add  
B4

add  
D1

add  
E2 + E3